Just when you thought there could not possibly be any more to say about
the subject, given the uncertainties inherent in the area, there is yet
another study. This one is from analysis of a large patient
registry in Finland. A total of 15,390 patients were included
in the analysis, over a period of 3.4 years. This study
confirms the finding that antidepressant use does lead to an increase
in suicide attempts. It also finds that there is a decrease
in actual death from suicide, and a decrease in
overall mortality.
href="http://archpsyc.ama-assn.org/cgi/content/abstract/63/12/1358">
href="http://archpsyc.ama-assn.org/cgi/content/abstract/63/12/1358">Antidepressants
and the Risk of Suicide, Attempted Suicide, and Overall
Mortality in a Nationwide Cohort
Jari Tiihonen, MD, PhD; Jouko Lönnqvist, MD,
PhD;
Kristian Wahlbeck, MD, PhD; Timo Klaukka, MD, PhD; Antti Tanskanen,
PhLic; Jari Haukka, PhD
Arch Gen Psychiatry. 2006;63:1358-1367.
Background It is unknown
if antidepressant treatment is associated with either increased or
decreased risk of suicide.Objective To estimate the risk of
suicide, attempted suicide, and overall mortality during antidepressant
treatments in a real-life setting with high statistical power.Design and Setting A cohort study in
which all subjects without psychosis, hospitalized because of a suicide
attempt from January 1, 1997, to December 31, 2003, in Finland, were
followed up through a nationwide computerized database.Participants A total of 15 390 patients
with a mean follow-up of 3.4 years.Main Outcome Measures The propensity
score–adjusted relative risks (RRs) during monotherapy with
the most frequently used antidepressants compared with no
antidepressant treatment.Results In the entire cohort, fluoxetine
use was associated with the lowest risk (RR, 0.52; 95% confidence
interval [CI], 0.30-0.93), and venlafaxine hydrochloride use with the
highest risk (RR, 1.61; 95% CI, 1.01-2.57), of suicide. A substantially
lower mortality was observed during selective serotonin reuptake
inhibitor use (RR, 0.59; 95% CI, 0.49-0.71; P<.001), and this
was attributable to a decrease in cardiovascular- and
cerebrovascular-related deaths (RR, 0.42; 95% CI, 0.24-0.71; P=.001).
Among subjects who had ever used any antidepressant, the current use of
medication was associated with a markedly increased risk of attempted
suicide (39%, P<.001), but also with a markedly decreased risk
of completed suicide (–32%, P=.002) and mortality
(–49%, P<.001), when compared with no current use of
medication. The results for subjects aged 10 to 19 years were basically
the same as those in the total population, except for an increased risk
of death with paroxetine hydrochloride use (RR, 5.44; 95% CI,
2.15-13.70; P<.001).Conclusions Among suicidal subjects who
had ever used antidepressants, the current use of any antidepressant
was associated with a markedly increased risk of attempted suicide and,
at the same time, with a markedly decreased risk of completed suicide
and death. Lower mortality was attributable to a decrease in
cardiovascular- and cerebrovascular-related deaths during selective
serotonin reuptake inhibitor use.
As always, one has to be cautious about drawing general conclusions
from this study. It is limited to residents of Finland.
It is limited to patients who had been hospitalized because
of a suicide attempt. It is limited to patients who did not
have psychosis.
There are some positives. The authors appear to have no
conflict of interest. That is, they are not drug company
shills. They had a large, comprehensive data set to work
with.
The thing about this study that is at least somewhat reassuring, is
that overall, the use of antidepressants was associated with a decrease
in overall mortality. Doctors tend to notice things like
that, because it is a bottom-line assessment. Regardless of
all the nuances and pros and cons and political and sociocultural
issues, if the end result is a reduction in mortality, then you know
you are on the right track. Or at least not very far off
track.
As for the specifics, it suggests that the old standby, fluoxetine, is
still a good choice. The deal with venlafaxine and
paroxetine suggests that they should not be first-line drugs, until
further notice.
As an aside, when patients ask me how to choose an antidepressant, I’ll
sometimes comment that “all other things being equal, if you need a
tiebreaker, the older drugs are preferred over the newer ones.”